ADC potential “standard of care” for some breast cancer patients
Drug Discovery World
FEBRUARY 21, 2023
The FDA has granted expanded approval for Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) for patients with HR-positive/HER2-negative metastatic breast cancer who have received hormonal therapy and at least two additional therapies in the metastatic setting.
Let's personalize your content